Filed by Sunesis Pharmaceuticals, Inc.
Pursuant to Rule 425 under the Securities Act of 1933, as amended
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934, as amended
Subject Company: Viracta Therapeutics, Inc.
(Commission File No. 000-51531)
Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of
its Recent End of Phase 2 Meeting with the FDA
Promising data show complete responses observed across multiple subtypes of
Epstein-Barr virus positive (EBV+) lymphoma; preliminary ORR/CR of 80%/40% in T/NK-NHL and 66%/33% in DLBCL
Recent End of Phase 2 Meeting supports advancement into single-arm registration trial
Registration trial for the treatment of relapsed/refractory EBV+ lymphomas to begin in 1H2021
PR Newswire, San Diego, December 7, 2020 Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology
company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+
lymphomas.
At the 62nd American Society of Hematology (ASH) Annual Meeting, Dr. Pierluigi Porcu
of Sidney Kimmel Cancer Center, Thomas Jefferson University, presented updated data from Viractas ongoing clinical trial evaluating its all-oral combination regimen of nanatinostat and valganciclovir for
the treatment of patients with R/R EBV+ lymphoma that had failed one or more prior therapies and lacked treatment options.
As of the data cutoff (October 27, 2020), 46 patients were enrolled (B-cell
non-Hodgkin lymphoma (B-NHL; n=10), T/NK-cell non-Hodgkin lymphoma (T/NK-NHL; n=15), immunodeficiency-associated lymphoproliferative disorder (IA-LPD; n=13) and Hodgkin lymphoma (HL: n=8). The number of median prior therapies was 2; 80% were
refractory to their last prior therapy and 80% had exhausted all prior therapies.
Key results include:
|
|
|
Complete responses were observed across multiple EBV+
lymphoma subtypes (diffuse large B-cell lymphoma (DLBCL), T/NK-NHL and IA-LPD); preliminary efficacy in Phase 2 is
consistent with Phase 1b results
|
|
|
|
Highly active in T/NK-NHL (n=10) with an overall response rate (ORR) of
80% (8/10) and complete response rate (CR) of 40% (4/10)
|
|
|
|
Encouraging activity in DLBCL (n=6) with an ORR of 66% (4/6) and a CR of 33% (2/6); both CRs were in
patients refractory to first-line R-CHOP
|
|
|
|
Generally well-tolerated; most common Grade 3/4 toxicities were reversible cytopenias with limited
extra-hematologic toxicity
|
|
|
|
Three patients (2 T/NK-NHL, 1 Hodgkin lymphoma) previously ineligible for
immunotherapy approaches were withdrawn from the trial to undergo stem cell transplantation and CAR-T cell therapy respectively
|
|
|
|
Median duration of response of 10.4 months
|
Page | 1